Senescent prostate cancer cells drive stromal remodeling through TGF-beta signaling
Researchers found that senescent epithelial cells secrete TGF-beta1 to reprogram fibroblasts into a matrix-remodeling state, which senolytic treatment can blunt.
Neoplasia (New York, N.Y.) · Lin C et al. · Paper published 1 Oct 2026
Using human prostate cancer specimens, single-cell datasets, Pten-deficient mice, and mouse cell cultures, researchers evaluated how senescent epithelial cells alter the tumor stroma. Senescence-associated markers increased with prostate cancer grade and concentrated primarily in epithelial cells. In both human datasets and Pten-knockout mice, epithelial senescence correlated with fibroblast matrix remodeling and collagen deposition. In cell culture experiments, doxorubicin-induced senescent mouse prostate cancer cells secreted elevated levels of TGF-beta1. Conditioned medium from these cells reprogrammed NIH/3T3 fibroblasts into a cancer-associated fibroblast-like state that boosted collagen deposition and matrix gene expression. Treating senescent cancer cells with the senolytic ABT-263 lowered their numbers, reduced TGF-beta1 release, and suppressed fibroblast activation. Furthermore, pharmacological inhibition of TGF-beta signaling decreased SMAD2 phosphorylation and partially reversed the matrix-remodeling phenotype.
Why it matters
The findings detail how the senescence-associated secretory phenotype directly remodels the extracellular matrix. They also demonstrate that senolytics can disrupt harmful epithelial-stromal communication in fibrotic microenvironments.
Caveats
Mechanistic experiments relied on in vitro mouse cell lines, drug-induced senescence models, and conditioned medium assays. Further research is needed to determine whether senolytic interventions effectively reverse stromal remodeling in vivo.
Written from the paper’s abstract, and every claim checked against it before publishing. Read the paper for the full methods and data.
The paper
Senescence-associated prostate cancer cells promote fibroblast reprogramming and extracellular matrix remodeling
Lin C, Guo Q, Lai S
Neoplasia (New York, N.Y.) · 1 Oct 2026 · Peer-reviewed
- Relevance
- Relevant
- News value
- Notable
- Evidence
- Cells
- Status
- Peer-reviewed
More on Cellular senescence
See allDasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
Nature metabolism · Koning M et al.
A distinct p21-driven macrophage senotype accumulates during aging and liver disease
Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with senolytics.
bioRxiv · Torres G et al.
DNA methylation proxies of senescence markers track human disease and mortality
The new blood-based tools estimate senescence gene activity to predict incident diseases, all-cause mortality, and clinical treatment responses.
medRxiv · Simpson DJ et al.
Bispecific T cell engager eliminates senescent cells in mice and nonhuman primates
Monitored by serum transaminase levels, low doses of the drug alleviated age-related pathologies without causing the hepatotoxicity seen at higher doses.
Aging cell · Deng J et al.
A deep learning score for cellular senescence predicts human mortality and disease risk
The proteomic biomarker tracked chronic illness risk in the UK Biobank and shifted following an 18-month multimodal exercise intervention.
Aging cell · Zhao S et al.